1.16

1.75% 0.02

Pre-market: 1.17 0.01 +0.86%

Bioxcel Therapeutics Inc (BTAI)

Overview News Price History Option Chain Financials Why BTAI Down? Discussions Forecast

Bioxcel Therapeutics Inc stock is traded at $1.16, with a volume of 823.27K. It is up +1.75% in the last 24 hours and up +1.75% over the past month. BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Previous Close:

$1.14

Open:

$1.16

24h Volume:

823.27K

Relative Volume:

1.02

Market Cap:

$35.82M

Revenue:

$680.00K

Net Income/Loss:

$-75.33M

P/E Ratio:

-0.1874

EPS:

-6.1898

Net Cash Flow:

$-57.38M

1W Performance:

+4.98%

1M Performance:

+1.75%

6M Performance:

-37.97%

1Y Performance:

-25.64%

1-Day Range:

$1.16

$1.27

1-Week Range:

$1.05

$1.27

52-Week Range:

$1.01

$8.08

Bioxcel Therapeutics Inc Stock (BTAI) Company Profile

Name

Bioxcel Therapeutics Inc

Sector

Healthcare (1104)

Industry

Drug Manufacturers - Specialty & Generic (88)

Phone

203-643-8060

Address

555 LONG WHARF DRIVE, NEW HAVEN, CT

Employee

Twitter

@bioxcel_tx

Next Earnings Date

2026-05-18

Latest SEC Filings

BTAI's Discussions on Twitter

Compare BTAI vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BTAI Bioxcel Therapeutics Inc	1.16	35.82M	680.00K	-75.33M	-57.38M	-6.1898
TAK Takeda Pharmaceutical Co Adr	15.77	49.83B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.07	40.04B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	33.69	39.23B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	79.95	33.52B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.57	23.33B	3.17B	1.29B	1.01B	27.09

Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Initiated	Rodman & Renshaw	Buy
Feb-21-24	Downgrade	UBS	Buy → Neutral
Aug-15-23	Downgrade	Mizuho	Buy → Neutral
Jul-17-23	Downgrade	Guggenheim	Buy → Neutral
Mar-10-23	Downgrade	Jefferies	Buy → Hold
Dec-01-22	Upgrade	Goldman	Sell → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-06-22	Reiterated	BofA Securities	Buy
Nov-15-21	Downgrade	Goldman	Neutral → Sell
Apr-09-21	Initiated	Berenberg	Buy
Feb-01-21	Initiated	UBS	Buy
Oct-30-20	Initiated	Goldman	Buy
Sep-02-20	Initiated	Jefferies	Buy
Aug-17-20	Reiterated	H.C. Wainwright	Buy
Jul-08-20	Reiterated	H.C. Wainwright	Buy
Jun-04-20	Initiated	Guggenheim	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Jan-08-20	Reiterated	H.C. Wainwright	Buy
Nov-12-19	Initiated	SunTrust	Buy

View All

Bioxcel Therapeutics Inc Stock (BTAI) Latest News

Jun 12, 2026

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill

Jun 12, 2026

Jun 11, 2026

BTAI Stock Gained 5% TodayWhat's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits

Jun 11, 2026

Jun 05, 2026

Attention BioXcel Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against BioXcel Therapeutics, Inc. (BTAI) and Encourages Investors to Contact the Firm - TMX Newsfile

Jun 05, 2026

Jun 03, 2026

BioXcel presents data on at-home agitation treatment trial By Investing.com - Investing.com India

May 28, 2026

BioXcel Therapeutics Presents New Data from Serenity At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia - marketscreener.com

May 28, 2026

BioXcel presents data on at-home agitation treatment trial - Investing.com

May 28, 2026

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting - The Manila Times

May 28, 2026

BioXcel Therapeutics Presents New Data from SERENITY - GlobeNewswire

May 28, 2026

May 27, 2026

BioXcel Therapeutics | 424B5: Prospectus - Moomoo

May 27, 2026

BioXcel Therapeutics Company Profile & Introduction - Moomoo

May 27, 2026

May 23, 2026

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock By Investing.com - Investing.com Nigeria

May 23, 2026

BioXcel Therapeutics chief legal officer sells $7,111 in stock By Investing.com - Investing.com Nigeria

May 23, 2026

BioXcel CFO Richard Steinhart sells $7,426 of stock By Investing.com - Investing.com India

May 23, 2026

BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock By Investing.com - Investing.com Nigeria

May 23, 2026

May 22, 2026

BioXcel Therapeutics CEO Mehta sells $21,108 in company stock - Investing.com India

May 22, 2026

BioXcel CFO Richard Steinhart sells $7,426 of stock - Investing.com UK

May 22, 2026

BioXcel Therapeutics chief legal officer sells $7,111 in stock - Investing.com

May 22, 2026

BioXcel Therapeutics CSO Frank Yocca sells $7,426 in company stock - Investing.com

May 22, 2026

BioXcel Therapeutics (BTAI) CSO exercises 17,500 RSUs, sells 6,845 shares for tax payment - Stock Titan

May 22, 2026

BioXcel Therapeutics (BTAI) executive sells shares after RSU vesting for taxes - Stock Titan

May 22, 2026

BioXcel (BTAI) CFO exercises 17,500 RSUs and sells 6,845 shares for taxes - Stock Titan

May 22, 2026

BioXcel Therapeutics (BTAI) CEO sells shares to cover RSU tax obligations - Stock Titan

May 22, 2026

BioXcel Shareholder Notice - TMX Newsfile

May 22, 2026

May 20, 2026

BioXcel Therapeutics (BTAI) Form 144: 19,419 RSUs vested, 30.9M shares outstanding - Stock Titan

May 20, 2026

BioXcel Therapeutics (NASDAQ: BTAI) notice to sell 6,560 vested restricted shares - Stock Titan

May 20, 2026

BioXcel Therapeutics (BTAI) Rule 144: 6,845 shares from vested RSUs - Stock Titan

May 20, 2026

[144] BioXcel Therapeutics, Inc. SEC Filing - Stock Titan

May 20, 2026

May 18, 2026

Is BioXcel Therapeutics (BTAI) Overvalued After Q1 2026? EPS Not - GuruFocus

May 18, 2026